Capricor Therapeutics (CAPR) to Release Earnings on Wednesday

Capricor Therapeutics (NASDAQ:CAPR) is set to announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Capricor Therapeutics Stock Down 0.8 %

Shares of NASDAQ:CAPR opened at $19.54 on Tuesday. The company has a market capitalization of $887.31 million, a price-to-earnings ratio of -21.01 and a beta of 4.00. The company has a 50 day moving average of $14.11 and a two-hundred day moving average of $8.14. Capricor Therapeutics has a 52-week low of $2.72 and a 52-week high of $23.40.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price target on shares of Capricor Therapeutics in a report on Friday, September 20th. Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Insiders Place Their Bets

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 12.00% of the stock is currently owned by company insiders.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.